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A B S T R A C T
Skin and soft-tissue infections (SSTIs) are a common indication for antibiotic use in Europe and are as-
sociated with considerable morbidity. Treatment of SSTIs, occasionally complicated by infection with
meticillin-resistant Staphylococcus aureus, can be resource intensive and lead to high healthcare costs.
For patients treated in an inpatient setting, once the acute infection has been controlled, a patient may
be discharged on suitable oral antibiotic therapy or outpatient parenteral antibiotic therapy. The re-
cently conﬁrmed eﬃcacy of single-dose (e.g. oritavancin) and two-dose (e.g. dalbavancin) infusion therapies
as well as tedizolid phosphate, a short-duration therapy available both for intravenous (i.v.) and oral use,
for treating SSTIs has highlighted the need for clinicians to re-evaluate their current treatment para-
digms. In addition, recent clinical trial data reporting a novel endpoint of early clinical response, deﬁned
as change in lesion size at 48–72 h, may be of value in determining which patients are most suitable for
early de-escalation of therapy, including switch from i.v. to oral antibiotics, and subsequent early hos-
pital discharge. The aim of this paper is to review the potential impact of assessing clinical response on
clinical decision-making in the management of SSTIs in Europe, with a focus on emerging therapies.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Skin and soft-tissue infections (SSTIs) encompass a wide spec-
trum of clinical presentations, depending on the anatomical site of
infection [1]. They range in severity from mild superﬁcial forms to
severe life-threatening infections that penetrate the deep subcu-
taneous tissues and/or require hospitalisation [2]. A variety of
acronyms and deﬁnitions are used to describe SSTIs, which can lead
to confusion among clinicians, including prescribers [3]. For example,
skin and skin-structure infection (SSSI) is a commonly used term
that can be considered synonymous with SSTI [4]. The term com-
plicated SSTI (cSSTI) is used to describe infections that are at the
extreme end of the clinical spectrum; cSSTIs are often accompa-
nied by some evidence of systemic sepsis [1]. The US Food and Drug
Administration (FDA) has introduced the term acute bacterial skin
and skin-structure infection (ABSSSI) to help delineate the types of
skin infections that should be assessed in registration trials of new
antibiotics [4]. ABSSSIs include cellulitis/erysipelas, wound infections
andmajor cutaneous abscesses, but exclude infections resulting from
animal or human bites, necrotizing fasciitis, diabetic foot infec-
tion and decubitus ulcer infection [4]. For clarity, the term SSTI will
be used here to describe all types of skin infection except where
speciﬁcally stated otherwise.
The aim of this article is to review how early assessment of the
patient’s response to treatment can help clinicians in Europe improve
the patient journey, such as shortening the hospital length of stay
(LOS) and optimising outpatient therapy, thereby addressing im-
portant antimicrobial stewardship goals. To achieve this aim, clinical
trials of recently licensed antimicrobials for the treatment of SSTI
(due both to susceptible and resistant strains of Staphylococcus
aureus) will be considered.
1.1. Clinical burden and epidemiology
SSTIs are a common indication for antibiotic use in Europe and
are associated with considerable morbidity [5]. Data from the Eu-
ropean Centre for Disease Prevention and Control (ECDC) estimated
that 4% of all healthcare-acquired infections (HAIs) reported between
2011 and 2012 were SSTIs, with surgical-site infections being the
second most frequently reported HAI (19.6%) [5]. During 2008 and
2009 there were 82,113 cellulitis hospital admissions in England and
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Wales with a mean hospital LOS of 7.2 days, and an estimated £133
million (€170 million; US$209 million) of costs were due to direct
inpatient bed stay [6].
In Europe, the most frequently isolated Gram-positive patho-
gens in SSTIs are S. aureus [including meticillin-resistant S. aureus
(MRSA) and meticillin-susceptible S. aureus (MSSA)], followed by
β-haemolytic streptococci [1,7,8]. In skin infections that have a more
complex aetiology, such as those resulting from necrotizing fascii-
tis, diabetic foot infection and ecthyma gangrenosum, the range of
pathogens is numerous and is dependent on the clinical setting [4,9].
The prevalence of MRSA varies greatly across Europe, with much
higher frequencies seen in southern and southeastern countries [10].
Based on the European Antimicrobial Resistance Surveillance
Network (ERAS-Net), the European population-weighted mean per-
centage for MRSA was 17.4% in 2014, ranging from 0.9% in the
Netherlands to 56.0% in Romania [10].
1.2. Resource implications
Treatment of hospitalised patients with SSTI in Europe is re-
source intensive and is associated with prolonged hospital LOS and
high healthcare costs [11,12]. The drivers of increased LOS are de-
scribed in Table 1. Patients with MRSA-SSTI experience a longer LOS
compared with patients with MSSA-SSTI, which can be further pro-
longedwhen the initial antibiotic treatment fails [12]. The acquisition
cost of antibiotics represents a relatively small proportion of the
overall cost of managing cSSTIs in hospitals. A 2009 study esti-
mated that for linezolid-treated patients, the per-patient total
treatment cost (comprising hospitalisation, antibiotic, inpatient tests
and aftercare charges) was €7778 [14]. The cost of the antibiotic
itself was €1595, representing ≈ 20% of the total. The same study
demonstrated that vancomycin treatment was associated with a
higher overall cost (€8777) despite the comparatively lower cost of
this drug (€964; ≈ 11% of the total) [14].
For inpatients, once the acute infection has been controlled and
there are no other reasons for continued hospitalisation, it should
be possible to discharge patients on suitable oral antibiotic therapy
or outpatient parenteral antibiotic therapy (OPAT) [15–17]. Treat-
ment outside of thehospital setting is generally preferredbypatients,
is relatively low cost and is aligned with antimicrobial stewardship
strategies [16,18]. Three new antibiotics (oritavancin, dalbavancin
and tedizolidphosphate) couldoffer additional opportunities for early
discharge of cSSTI patients [19–21], in keeping with antimicrobial
stewardship initiatives. Oritavancin and dalbavancin offer, respec-
tively, a single-dose or two-infusion dose of treatment, representing
a novel paradigm for treating such infections [22,23]. Tedizolid
phosphate offers both intravenous (i.v.) and oral treatment options
for a 6-day treatment duration [24,25]. Phase 3 trials of tedizolid
phosphate demonstrated that 6 days of therapy, which is a shorter
duration than that recommended formost other antibiotics for this
indication [26–29], was non-inferior to 10 days of therapy with
linezolid [24,25], providing evidence-based reassurance for clini-
cians to consider shorter durations of treatmentwith this antibiotic.
2. Management of skin and soft-tissue infections
Management of SSTIs is dependent on the clinical presentation
and the severity of the infection [2]. In general, a combination of
surgical debridement or drainage and antibiotic treatment is used
to treat the infection [1], although incision and drainage, without
the need for antibiotics, is usually suﬃcient for treating simple ab-
scesses or boils [30]. Determining the level of disease severity is an
important ﬁrst step in the clinical management of SSTIs in order
to determine the type of care and empirical therapy [31]. Failure
to do this can lead to inappropriate prescribing, with overtreat-
ment of mild SSTIs and undertreatment of severe SSTIs having been
reported previously [32,33]. For non-necrotizing SSTIs, including
those caused by MSSA, commonly used antibiotics include peni-
cillin G, cloxacillin, ceftriaxone and clindamycin [3]. The Infectious
Diseases Society of America (IDSA) recommends early empirical
therapy with an anti-MRSA agent for all hospitalised patients with
SSTI [2]. These treatments are discussed below.
In Europe, where there are vast disparities in the prevalence of
MRSA between countries [10], emphasis should be placed on un-
derstanding local epidemiology patterns for MRSA to ascertain the
level of risk and the requirement for antibiotic therapy directed
towards this pathogen [3]. Initial treatment of SSTIs is usually em-
pirical because microbial culture results are generally not available
for several days, and patients with SSTI beneﬁt from rapid initia-
tion of appropriate therapy [34]. The importance of early treatment
for MRSA-SSTI was underscored by a recent retrospective study
showing that patients who received therapy 1 day or 2 days after
their date of diagnosis with cSSTI had a signiﬁcantly shorter dura-
tion of i.v. therapy and hospital LOS than patients whose treatment
was initiated ≥3 days after their date of cSSTI diagnosis [13].
The ﬁrst-line antibiotic treatments recommended for MRSA-
cSSTI in Europe are the glycopeptides vancomycin and teicoplanin.
Additional antibiotics recommended by guidelines for cSSTI with
proven or suspected MRSA involvement include linezolid,
daptomycin and tigecycline (Table 2), with 7–14 days of therapy gen-
erally being recommended [35,36,38,40–43]. Several new antibiotics
approved in Europe for the treatment of ABSSSIs (oritavancin,
dalbavancin and tedizolid phosphate) [19–21] or cSSTI (ceftaroline)
[44] are not yet discussed in European guidelines. The use of in-
appropriate initial antibiotic treatment can be associated with
adverse clinical outcomes, increased morbidity and mortality, and
increased hospital LOS or costs [41,45–48], highlighting the impor-
tance of establishing a microbiological diagnosis promptly.
3. Treatment patterns in Europe
The REACH study was a large, multicentre observational study
that examined treatment patterns, healthcare resource utilisation
and clinical outcomes for hospitalised patients with cSSTI (n = 1995)
in 10 European countries from 2010 to 2011 [8,12,49]. This analy-
sis revealed that of cSSTI patients managed with antibiotics, 60.3%
received penicillin with or without a β-lactamase inhibitor, 5.2% re-
ceived vancomycin, 4.4% received daptomycin and 1.9% received
linezolid as their initial antibiotic treatment [8], whereas teicoplanin
and tigecycline were less commonly used.
A survey conducted in 2014 among 350 respondents from Eu-
ropean infection societies indicated that the preferred initial i.v.
Table 1
Drivers of increased length of stay for hospitalised patients with complicated skin
and soft-tissue infections (cSSTIs) (adapted from Nathwani et al) [13].
• Increased length of intravenous (i.v.) therapy
• History of i.v. drug abuse
• High number of co-morbidities
• Patients with deep or extensive cellulitis (versus patients with a surgical
site or post-traumatic wound infection)
• Infection in the torso or abdomen (versus upper extremity infection)
• Infection developed ≥4 days after admission
• Severe sepsis
• Surgery
• Late initiation of antibiotic treatment (≥3 days after the date of cSSTI
diagnosis)
• Failed/inappropriate initial/empirical therapy
• No i.v.-to-oral antibiotic switch options and/or lack of corresponding
protocol
• Not discharged from the hospital with outpatient parenteral antibiotics
• Cultural attitudes of physicians toward completion of i.v. course in hospital
• Healthcare system reimbursement policies
• Lack of awareness of treatment/administration options
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treatment choice for a SSTI patient with MRSA was glycopeptides
(34.5% vancomycin, 20.3% teicoplanin) [50]. Clinical eﬃcacy was the
main driver behind the respondents’ choice of antibiotic [50]. The
majority (79%) would switch to oral therapy once the patient was
stable, whilst 21% would have the patient complete the treatment
with the same i.v. antibiotic (7% in hospital and 14% in OPAT). In-
terestingly, 70% of respondents believed that ≥10 days was the
optimum duration of therapy for patients with MRSA-cSSTI [50].
Country-speciﬁc variations in MRSA-cSSTI treatment patterns
across 12 European countries were also evaluated in a recent ret-
rospective medical chart review [18]. Of the 1502 patients identiﬁed
between 2010 and 2011, 1468 (97.7%) received conﬁrmed MRSA-
targeted therapy andmost patients (81.5%) received i.v. therapy only.
Only 10.7% were switched to an oral antibiotic (in-hospital i.v.-to-
oral switch rates ranged from 2.0% to 20.2% by country). Overall,
32.7% of patients were discharged from hospital on MRSA-targeted
therapies (ranging from 18.0% to 49.7%), and 92.7% and 7.3% of these
patients were discharged on oral therapy and OPAT, respectively [18];
however, large variation was found in antibiotic treatment pat-
terns across Europe (Fig. 1).
4. Opportunities for a change in antibiotic management
In modern clinical practice, there is a drive to promote prudent
and rational use of antimicrobials to select the most effective, safe
and narrow-spectrum antimicrobial agent that has the least capac-
ity for theemergenceof resistanceorhealthcare-associated infections,
within a framework of antimicrobial stewardship [51]. However, ap-
proaches to antimicrobial stewardship vary considerably among
countries [52].With speciﬁc regard toMRSA infections, there appears
to be no single European-wide approach to antimicrobial steward-
ship (e.g. disparities in the availability of discharge, i.v.-to-oral switch
and OPAT protocols), although there are signs that clinicians are be-
comingmore familiarwith the relevant concepts and standards [50].
The need to provide more cost-effective healthcare, an addition-
al antimicrobial stewardship objective [52], has stimulated a change
in healthcare delivery in Europe. This is illustrated by a signiﬁcant
reduction in inpatient bed capacity, paralleled by investment in and
support for outpatient hospital care, ambulatory therapy centres and
home care [53]. Many approaches to the management of cSSTI are
aimed at reducing LOS as a means of increasing the eﬃciency and
cost effectiveness of the hospital [54,55].
OPAT programmes enable patients to receive i.v. antibiotics after
hospital discharge, but require additional resources and are not avail-
able to all patients in Europe [56–58]. A variety of old and new agents
are available for once-daily i.v. treatment [42], and these can be suit-
able for use as part of an OPAT programme or within the emergency
department setting [59].
Evidence also suggests that many patients who require at-
home antibiotic therapy can be treated with an oral agent after
hospital discharge [16]. Early switch (ES) strategies promote switch-
ing patients from i.v. to oral antibiotics, and early discharge (ED)
strategies enable patients to ﬁnish treatment after hospital dis-
charge. The eligibility criteria for i.v.-to-oral switch of antibiotic
therapy and ED are described in Table 3. ES and ED strategies lead
to reductions in the volume of antibiotic use, reduce the risk of
healthcare-associated complications and infections, require few ad-
ditional resources and are considered to be relatively low-cost and
high-impact antimicrobial stewardship strategies [13,18]. Al-
though healthcare systems vary signiﬁcantly across European
countries, a criteria-based approach could provide ES and ED op-
portunities for certain patients with cSSTI, thereby improving both
economic and patient outcomes [13,18].
The potential beneﬁts of ES and ED strategies for hospitalised
patients withMRSA-cSSTI were illustrated in a retrospective medical
chart review of patients (n = 1542) from 12 European countries in
2010–2011. This study found that patients with MRSA-cSSTI who
switched from i.v. to oral antibiotic therapy had 5.3 fewer i.v. days
(P < 0.001) and 1.9 fewer inpatient days (P = 0.162) compared with
those who received i.v. therapy for the entire treatment duration
[61]. In addition, the authors estimated that more than one-third
of patients were eligible for ES and ED, which could result in sub-
stantial reductions in i.v. days and bed-days, with potential savings
of €2000 per ED-eligible patient [61]. Implementing clear strate-
gies to evaluate patients for ES/ED eligibility can result in improved
antibiotic stewardship, a reduction in volume of antibiotic use, more
rapid i.v.-to-oral switch, a reduction in LOS and overall cost savings
[16].
Table 2
Antibiotic options available for the treatment of meticillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections (cSSTIs) according to European guide-
lines a [34–38].
Antibiotic Route Dosing regimen Mechanism of action Indications Reference
Vancomycin i.v. 500 mg q6h or 1 g q12h Cell-wall synthesis
inhibitor
Severe infection caused by Gram-positive
bacteria susceptible to vancomycin that cannot
be treated with, or failed to respond to, or are
resistant to other antibiotics such as penicillins
and cephalosporins
[28]
Teicoplanin i.v. and
i.m.
6 mg/kg q12h for three administrations
followed by 6 mg/kg once daily (for cSSTI)
(treatment duration dependent on clinical
response)
Cell-wall synthesis
inhibitor
cSSTI, bone and joint infection, hospital-
acquired pneumonia, complicated urinary
tract infection, infective endocarditis,
peritonitis associated with continuous
ambulatory peritoneal dialysis, and
bacteraemia that occurs in association with
any of the indications listed above
[27]
Linezolid i.v. and
oral
600 mg twice daily for 10–14 days Protein synthesis
inhibitor
Pneumonia (nosocomial and community-
acquired) and cSSTI due to Gram-positive
pathogens
[29]
Daptomycin i.v. cSSTI without S. aureus bacteraemia: 4 mg/kg
once daily for 7–14 days
cSSTI with S. aureus bacteraemia: 6 mg/kg once
daily for 14 days
Inhibition of protein,
DNA and RNA
synthesis
cSSTI, right-sided infective endocarditis due to
S. aureus, and S. aureus bacteraemia when
associated with right-sided endocarditis or
with cSSTI
[26]
Tigecycline i.v. 100 mg followed by 50 mg q12h for 5–14 days Protein synthesis
inhibitor
cSSTI (excluding diabetic foot infection) and
complicated intra-abdominal infections
[39]
i.v., intravenous; q6h, every 6 h; q12h, every 12 h; i.m., intramuscular.
a Newer options such as tedizolid phosphate, oritavancin, dalbavancin and ceftaroline are approved for use in Europe for the treatment of cSSTI, but are not yet discussed
in guidelines.
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5. Early assessment of response to therapy
When treating a patient with SSTI with i.v. antibiotics, it is good
clinical practice to review the response to treatment on a daily basis.
However, a clinical review at 48–72 h post-initiation is critical for
deciding whether to stop or continue with the current treatment,
to switch to an oral antibiotic, to change the antibiotic or to initi-
ate OPAT, as outlined in the ‘Start Smart—Then Focus’ antimicrobial
stewardship initiative from Public Health England [15]. Clinical out-
comes around Day 3 have strong therapeutic importance. Early
indication of treatment failure can guide necessary changes to an-
tibiotic treatment, thus avoiding prolonged use of inappropriate
treatment, which has been reported to increase overall morbidity
and mortality [48]. In addition, the optimal time to re-assess the
antibiotic treatment plan is on Days 2–3 of i.v. therapy when culture
results, which were taken on initiation of antibiotic therapy, have
been made available [60], along with other diagnostic informa-
tion and assessments of patient response.
Recent FDA guidance on the conduct of clinical trials for SSTIs
has suggested changes to clinical trial design and conduct [4,62].
Notable revisions included new disease state deﬁnitions, new
primary endpoint deﬁnitions, early assessment of these end-
points and updated guidance on patient inclusion/exclusion criteria
(Table 4). The primary eﬃcacy endpoint in non-inferiority studies
for SSTIs in Europe and the USA has historically been resolution of
signs and symptoms of infection 7–14 days after the end of therapy
(EOT) [9,63]. The new primary endpoint for clinical studies of ABSSSI,
referred to as early assessment of clinical response, is a ≥20% re-
duction in lesion size at 48–72 h compared with baseline. It is
recommended that clinical trials for ABSSSIs should also incorpo-
rate the key secondary endpoints of sustained clinical response at
EOT and 7–14 days after EOT [referred to as post-therapy evalua-
tion (PTE)] [4]. Such an approach would enable the use of the trial
results for supporting licensing submissions to multiple regulato-
ry authorities, including the European Medicines Agency (EMA)
[64].
6. Antibiotic agents that have been evaluated using the new
FDA endpoints
Three new antibiotics (oritavancin, dalbavancin and tedizolid
phosphate) recently approved in the USA and Europe for the
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Fig. 1. Country-speciﬁc initial antibiotic treatment patterns for complicated skin and soft-tissue infections (cSSTIs) due to meticillin-resistant Staphylococcus aureus (MRSA)
(adapted from Eckmann et al) [18]. Note: percentages calculated from a denominator based on the number of patients with MRSA-active therapy. a Drug groups were not
mutually exclusive; multiple medications could be used simultaneously. b Includes clindamycin, ﬂuoroquinolones (ciproﬂoxacin, levoﬂoxacin, moxiﬂoxacin, norﬂoxacin and
oﬂoxacin), rifampicin, trimethoprim/sulfamethoxazole, doxycycline, ertapenem, fusidic acid, gentamicin, imipenem, meropenem, minocycline, pristinamycin, quinupristin/
dalfopristin and trimethoprim.
Table 3
Patient eligibility criteria for i.v.-to-oral switch of antibiotic therapy and early dis-
charge (adapted from Mertz et al [60] and Nathwani et al [61]).
Early switch is recommended if all inclusion criteria are fulﬁlled, all exclusion
criteria are absent and if an appropriate oral regimen is available
Eligible for oral switch
• i.v. antibiotics for >24 h
• Afebrile (temperature <38 °C) for >24 h
• Clinical improvement or stable infection
• WBC count normalising, WBC count of 4 × 109/L to 12 × 109/L
• No unexplained tachycardia
• Systolic blood pressure ≥100 mmHg
• Patient tolerates oral ﬂuids/diet and is able to take oral medications with
no gastrointestinal absorption problems
Not eligible for oral switch
• Cutaneous abscess not treated with incision and drainage; severe
soft-tissue infection; osteomyelitis; septic arthritis
Eligible for early discharge
• All early switch eligibility criteria listed above have been met
• No other reason to stay in hospital except for infection management
• Stable mental status
• Stable co-morbid illness
• Stable social situation
i.v., intravenous; WBC, white blood cell.
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treatment of ABSSSIs in adults were studied in phase 3 clinical trials
that were designed largely in line with the new FDA guidance
(Table 5). Whilst the oritavancin, dalbavancin and the ﬁrst tedizolid
phosphate (ESTABLISH-1) phase 3 trials used the 2010 FDA draft
guidance [22,23,25,66], the tedizolid phosphate ESTABLISH-2 trial
was prospectively designed to reﬂect all of the key elements of the
2013 ﬁnal guidance [24]. Both the draft and ﬁnal guidance recom-
mended early assessment at 48–72 h [4,68]. The primary endpoint
in the 2010 draft FDA guidance was cessation of spread or reduc-
tion in size of the lesion at 48–72 h compared with baseline as well
as resolution of fever [68]. The primary endpoint in the 2013 ﬁnal
guidancewas a ≥ 20% reduction in ABSSSI lesion size at 48–72 h com-
pared with baseline [4].
Oritavancin is a lipoglycopeptide with bactericidal activity against
Gram-positive pathogens [21]. In the phase 3 SOLO I and II trials,
a single 1200 mg dose of oritavancin was shown to be non-inferior
to twice-daily vancomycin administered for 7–10 days for the treat-
ment of ABSSSIs caused by Gram-positive pathogens [23,66]. In
addition, there was >85% concordance (agreement correlation)
between success at the 48–72-h assessment and the PTE [69]. The
positive predictive values (PPVs) of the approaches to assess early
clinical response [(i) cessation of spreading or reduction in size of
baseline lesion, absence of fever and no rescue antibiotics at 48–
72 h and (ii) ≥20% reduction in lesion area at 48–72 h] were ≈ 95%,
and the negative predictive values (NPV) were ≈ 20% [69]. Al-
though early positive clinical response at 48–72 h was highly
predictive of clinical cure of ABSSSI at 7–14 days post-therapy, lack
of early clinical response was only rarely predictive of clinical failure
[69], which was expected, since overall cure is dependent on an-
tibiotic treatment as well as the natural course of the infection.
Dalbavancin, also a lipoglycopeptide, is bactericidal in vitro against
Gram-positive pathogens [19]. DISCOVER 1 and 2 were identically
designed non-inferiority phase 3 trials of dalbavancin (1000mg dose,
followed 1 week later by 500mg) for the treatment of ABSSSIs [22].
Patients received dalbavancin i.v. on Days 1 and 8 or vancomycin
i.v. for ≥3 days with the option to switch to oral linezolid to com-
plete 10–14 days of therapy. Analysis of the primary endpoint of
early clinical success showed non-inferiority of dalbavancin in both
DISCOVER 1 and 2. Patients achieving cessation of lesion spread
after 72 h of antibiotic treatment had a >90% chance of being cured
at EOT [70]. All combinations of response assessed (cessation of
spread, cessation of spread plus absence of fever, cessation of spread
plus worsening pain, absence of fever and >20% reduction in lesion
Table 4
Summary of key points of the 2013 US Food and Drug Administration (FDA) guid-
ance on clinical trials of acute bacterial skin and skin-structure infections (ABSSSIs)
[4].
Inclusion criteria
• Patients with cellulitis/erysipelas, wound infection or major cutaneous
abscess
• Lesions should have a minimum surface area of 75 cm2 (lesion size
measured by the area of redness, oedema or induration)
Exclusion criteria
• Patients with medical conditions that would alter the interpretation of a
primary endpoint (e.g. patients with neutropenia)
• Patients with suspected or conﬁrmed osteomyelitis
• Patients with suspected or conﬁrmed septic arthritis
• Patients who received >24 h of effective antibiotic therapy for treatment of
current ABSSSI
• Number of patients enrolled with major cutaneous abscesses should be
≤30% of the total study population
• Primary endpoint is ≥20% reduction in primary lesion size at 48–72 h
compared with baseline (early assessment)
• Secondary endpoint is resolution of ABSSSI evaluated at 7–14 days after
completion of therapy (post-therapy evaluation)
Table 5
Antibiotics indicated for skin and soft-tissue infection (SSTI) that have been assessed in newer clinical trials that evaluated both early clinical response as well as end of
therapy (EOT) and/or post-therapy evaluation (PTE) response.
Antibiotic a Dosing regimen
in clinical trials
Potential option
for oral switch
therapy
Potential option
for OPAT
Clinical response:
Early assessment
vs.
EOT or PTE
Tedizolid phosphate 200 mg once daily
for 6 days
Yes Yes Pooled ESTABLISH-1 and -2 studies [65]:
81.6% tedizolid phosphate vs. 79.4% linezolid in the ITT population at 48–72 h
vs.
86.7% tedizolid phosphate vs. 86.8% linezolid in the ITT population at PTE (7–14
days after EOT)
Oritavancin Single 1200 mg
dose
No Yes SOLO I study [23]:
82.3% oritavancin vs. 78.9% vancomycin in the MITT population at 48–72 h
vs.
79.6% oritavancin vs. 80.0% vancomycin in the MITT population at PTE (7–14
days after EOT)
SOLO II study [66]:
80.1% oritavancin vs. 82.9% vancomycin in the MITT population at 48–72 h
vs.
82.7% oritavancin vs. 80.5% vancomycin in the MITT population at PTE (7–14
days after EOT)
Dalbavancin 1000 mg followed
1 week later by
500 mg
No Yes Pooled DISCOVER 1 and 2 studies [22]:
79.7% dalbavancin vs. 79.8% vancomycin/linezolid in the ITT population at
48–72 h
vs.
90.7% dalbavancin vs. 92.1% vancomycin/linezolid in the per-protocol population
at EOT
Ceftaroline 600 mg every 12 h
for 5–14 days
No Yes Pooled CANVAS 1 and 2 studies [67]:
74.0% ceftaroline vs. 66.2% vancomycin plus aztreonam in the E-MITT population
at Day 3
vs.
87.3% ceftaroline vs. 85.4 % vancomycin plus aztreonam in the E-MITT
population at TOC visit (8–15 days after EOT)
OPAT, outpatient parenteral therapy; ITT, intent-to-treat; MITT, modiﬁed intent-to-treat; E-MITT, exploratory modiﬁed intent-to-treat; TOC, test-of-cure.
a All four of these antibiotics are approved in Europe for the treatment of cSSTI [19–21,44].
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size) had ≥88% sensitivity and PPV. The NPV ranged from 28% to 80%
because some early failures were ultimately successes at EOT. Ad-
dition of the criterion ‘worsening of pain relative to baseline’
improved the NPV to 80% and the speciﬁcity of the Day 3 assess-
ment of cessation of spread [70]. Thus, in these trials patients who
did not achieve cessation of spread at 72 h and had worsening of
pain had an 80% chance of ultimately failing therapy [70].
Tedizolid phosphate is an oxazolidinone antibiotic drug with bac-
tericidal activity in vivo and bacteriostatic activity in vitro against
Gram-positive pathogens [20,71]. In ABSSSI, the recommended
dosage of tedizolid phosphate is 200 mg administered once daily
for 6 days, either orally (with or without food) or as an i.v. infu-
sion over 1 h [20]. ESTABLISH-1 (oral only dosing) [25] and
ESTABLISH-2 (i.v.-to-oral dosing; optional oral step-down could occur
24 h after treatment initiation if pre-deﬁned conditions were met)
[24] were non-inferiority phase 3 trials of tedizolid phosphate for
the treatment of ABSSSIs. Clinical response in these trials was
analysed using varied endpoint deﬁnitions and criteria, therefore
allowing an opportunity to evaluate the concordance between
primary endpoints assessed in clinical trials and those more com-
monly used in clinical practice. In a combined analysis of the two
ESTABLISH trials, high concordance (93%) between early clinical re-
sponse at 48–72 h and clinical success at PTE was observed [65].
In addition, early clinical response (e.g. 20% lesion area reduction)
was strongly associatedwith investigator-assessed treatment success
(based on resolution of signs and symptoms) at the PTE visit, re-
gardless of ABSSSI type or hospitalisation status, with a high PPV
of >96% and a low NPV ranging mostly from 11% to 30% [72]. These
ﬁndings support the validity of a positive early response as an in-
dicator of long-term success. In contrast, early clinical failure based
on lesion area assessments had a low predictive ability for
investigator-assessed treatment failure at the PTE visit [72]. Since
changes in lesion size are generally not assessed in clinical prac-
tice, the potential utility of this approach for making real-world
treatment decisions is limited. However, the ESTABLISH data also
suggested that patients assessed as improving or stable at 48–
72 h based on the investigator’s clinical judgement had a high
likelihood of investigator-assessed success at the PTE visit (PPV > 94%)
[65]. The high concordance between programmatic early clinical re-
sponse and late response at PTE strongly support the use of early
clinical response to replace late response at PTE as a new regula-
tory primary endpoint. In addition, the high PPV of investigator-
assessed early clinical response for late response at PTE means that
clinician assessment of early clinical response could possibly be
useful in making treatment decisions (e.g. if a patient is stable after
48–72 h of antibiotic treatment, the physician may be conﬁdent that
the patient will have an overall cure with this therapy at EOT and
no change in therapy would be necessary). Further investigation of
investigator-assessed early clinical response is required.
7. Perspective on the real-world utility of early clinical
assessment of treatment outcomes in complicated skin and
soft-tissue infections and potential impact on early discharge
Following the release of the 2010 draft FDA guidance on the
conduct of clinical trials for ABSSSIs, the IDSA, which represents
>9000 clinicians, reported a lack of clinical relevance of the early
assessment endpoint and stated that the endpoint was irrelevant
to clinical success and was only indicative of clinical failure [73].
However, as described above, consistency between early and post-
therapy clinical responses was shown in six different phase 3 clinical
trials, thus supporting the relevance of this assessment to clinical
practice. Furthermore, in a study of management practices in Eu-
ropean hospitals, cSSTI patients who showed an early response to
treatment [<72 h; deﬁned as (i) resolution of fever AND some in-
dication of lesion improvement or stability, or (ii) lesion improvement
or stability OR resolution of local signs and symptoms] were less
likely to require therapy modiﬁcation and showed improved clin-
ical outcomes and lower resource use than patients without an early
response [49]. Finally, whilst there are no formal recommenda-
tions for early assessment in the UK, it is common practice to
accommodate patients with SSTI who do not have sepsis in a short-
stay ward, limited usually to a 24-h period. If they have shown
clinical response within that time, further treatment in an outpa-
tient setting can be considered. Speciﬁc criteria for early assessment
with early appropriate discharge and the cost implications of this
strategy in the UK have been published [16,17].
For patients with documented clinical improvement and who
are able to tolerate oral therapy, the aim should be to step-down
(streamline) therapy to the oral route as soon as possible [50].
Options for oral switch in the treatment of suspected or docu-
mentedMRSA-cSSTI include linezolid and tedizolid phosphate. Some
clinicians consider oral therapywith trimethoprim/sulfamethoxazole
(cotrimoxazole), and although effective in many circumstances (e.g.
MRSA-bacteraemia [74]), its eﬃcacy in severe cSSTI has not been
shown in randomised clinical trials [75]. To provide an illustrative
example for i.v.-to-oral switch, a case study is presented in Box 1.
In choosing an appropriate step-down oral antibiotic, the same
active antibiotic in oral form and high bioavailability could also be
considered. Clinical trials have shown that linezolid and tedizolid
phosphate have high oral bioavailability and comparable clinical
success rates [24,25]. Whilst the overall incidence of adverse events
was similar, patients who received tedizolid phosphate for 6 days
reported fewer gastrointestinal disorders (nausea, vomiting and di-
arrhoea) than patients who received linezolid for 10 days [65].
Tedizolid also led to a lower incidence of abnormally low platelet
and neutrophil counts 7–9 days after the start of therapy and at EOT
(Days 11–13) [65]. This is of importance because myelosuppression
is a known adverse event associated with the use of linezolid after
Box 1. Skin and soft-tissue infection (SSTI) case report of intravenous (i.v.)-to-oral switch.
A 57-year-old female with type 2 diabetes mellitus presented with swelling, redness and pain in her left lower leg. There was no ﬂuctuation, but the infected soft
tissue was erythematous and indurated with early development of a blister but no discharge. The patient had a temperature of 38 °C, a pulse of 84 beats per min
and a blood pressure of 140/85 mmHg. Early blood tests showed a white blood cell count of 10.2 × 109/L with slight neutrophilia and a C-reactive protein of 112 mg/L.
Other parameters were within normal ranges.
The patient had previously been colonised with meticillin-resistant Staphylococcus aureus (MRSA) in the nose and had a previous MRSA wound infection. She had a
history of penicillin allergy (rash) but was administered a single dose of 2 g ceftriaxone in the emergency department. On the ward, the patient was switched to
oral linezolid as she no longer met the systemic inﬂammatory response syndrome criteria, could take oral medication, and had a history of penicillin allergy and
previous MRSA. The patient responded well over the next 24 h with improvement of the erythema and fever and was discharged early to complete the course of
linezolid for 7 days in the community.
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2 weeks of drug administration; of note, these adverse events did
not result in clinical complications of bleeding or discontinuation
of treatment in either treatment group. The clinical relevance of these
differences with regards to longer duration of tedizolid phosphate
dosing is unknown.
High concordance between early and late clinical response could
facilitate ED of patients on i.v. or oral therapy, leading to impor-
tant positive cost implications. The clinician may be able to use early
response, along with other clinical parameters, to assess patients
for ES/ED. OPAT has been championed as an approach to ED because
it may reduce the cost of treatment and is preferred by patients over
i.v. administration in a hospital [76]. However, the use of OPAT with
many of the current parenteral agents is challenged by the avail-
ability of oral formulations of linezolid and tedizolid phosphate and
by longer-acting agents such as oritavancin and dalbavancin, which
either avoid or minimise the need for additional infusions. Consid-
erations such as patient preference and adherence are also relevant
in the choice of i.v. versus oral therapy. In a small survey of UK pa-
tients treated for antibiotic-resistant Gram-positive infections (n = 12),
there was a preference for discharge on oral over i.v. therapy, albeit
this was dependent on the formulations being of equal eﬃcacy [77].
There are limited data on adherence to oral therapies for cSSTI;
however, ﬁndings for other infections indicate that adherence is
higher with once-daily doses and shorter treatment regimens
[78–83].
Some patients with SSTI may be entirely managed in an outpa-
tient setting. This approach to management may be particularly
applicable to oral or longer-acting i.v. agents and may help to avoid
hospitalisation. This approach may also provide an alternative when
there is no OPAT service or the patient proﬁle suggests a high prob-
ability of poor participation in OPAT or compliance with oral therapy
[56,60,61]. However, the selection of appropriate patients is criti-
cal. In this context, longer-acting antibiotics (i.e. a single infusion
of oritavancin or two doses of dalbavancin, 1 week apart, with review
Fig. 2. Treatment algorithm for managing skin and soft-tissue infections (SSTIs) based on early clinical response. Note: long-acting infusion therapy, single dose of oritavancin
or two doses of dalbavancin 7 days apart. i.v., intravenous; OPAT, outpatient parenteral antibiotic therapy.
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at 48–72 h to ensure response) may be suitable for patients with
limited access to or interaction with healthcare systems (e.g. the
homeless, elderly, military personnel, i.v. drug abusers and those
in rural areas).
In light of the new early clinical response endpoint and the data
surrounding the relevance of utilising this endpoint, we updated
the treatment algorithm pathway developed by Eron et al [84] for
themanagement of SSTIs to include this assessment (Fig. 2). It shows
how new drugs, either oral with short duration or i.v. once a week,
may inﬂuence current decision-making in themanagement of cSSTIs.
Our aim is to encourage further debate and research about intro-
ducing these new concepts and treatment paradigms into current
care. We accept that further research (retrospective analysis of clin-
ical practice and prospective, real-world studies) is required to
address how clinicians can deﬁne and assess early clinical re-
sponse in an easy and objective manner.
8. Conclusions
SSTIs require early recognition and prompt management as, de-
pending on their severity, they can lead to considerable morbidity
andmortality and represent a major economic burden to the health-
care system. Recent clinical trials have demonstrated concordance
between early clinical response at 48 h and the PTE. In general prac-
tice, physicians may wish to consider an assessment of early clinical
response as part of their overall decision-making process when as-
sessing the likelihood of sustained response, so as to determine the
most effective approach to reducing the patient’s inpatient stay.
Because these data will require further veriﬁcation and understand-
ing, clinicians should display caution and ensure appropriate means
of patient monitoring/follow-up to minimise any unintended con-
sequences of early changes in treatment. Initial ﬁndings from clinical
studies with oxazolidinones suggest that early assessment of an-
tibiotic treatment response by clinicians—without having to take
the burdensome route of lesion area measurement—may be valu-
able in predicting late clinical response, and we recommend that
this topic be investigated further in prospective studies. For example,
it would be of great interest to studywhich routinely assessed patient
and diagnostic factorsmay be useful for objectively determining early
response in real-world clinical practice. Having this information avail-
able could greatly facilitate clinical decision-making in the
management of cSSTIs, such as early hospital discharge or the po-
tential to switch to an oral formulation of the same agent or step-
down to a different antibiotic agent.
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